GO:1904854 proteasome core complex binding

GO:1904854, proteasome core complex binding, is a molecular function term describing the selective physical association of a protein with the proteasome core complex, also known as the 20S core particle. The proteasome is the major ATP-dependent protease of eukaryotic cells and is built from a catalytic 20S core particle (CP) capped by one or two 19S regulatory particles (RP) to form the 26S proteasome. Because the CP is a self-compartmentalized barrel, proteins that bind it must recognize specific surfaces on the alpha- or beta-rings, and this binding often controls assembly, substrate access, or catalytic output. The term therefore captures a functionally important interface between the core particle and its many interacting partners. Researchers care about GO:1904854 because core-complex binding is not a passive event. Assembly chaperones such as Pba3 and Pba4 bind early alpha-ring intermediates and are required for correct CP formation. Regulatory factors, including proteasome-associated deubiquitinases, bind the core or the 19S particle and tune degradation. Ubiquitin-like modifiers such as FAT10, together with NUB1L, cooperate to activate the 26S proteasome, illustrating how core-complex-associated binding events can change proteolytic capacity. In addition, a small tRNA-binding protein has been shown to interact with an archaeal proteasome complex, indicating that core-complex binding is evolutionarily ancient and not limited to canonical regulators. From a disease perspective, perturbations in proteasome core complex binding and assembly contribute to cancer, neurodegeneration, and host-pathogen interactions. TRIM7, an E3 ubiquitin ligase, inhibits enterovirus replication and promotes emergence of a viral variant with increased pathogenicity, linking ubiquitin-dependent proteolysis to antiviral defense. K48-ubiquitin-dependent proteases also cut up post-ER proteins, connecting core-complex-associated degradation to ER quality control. This article integrates the QuickGO definition with verified literature to explain the mechanism, key genes, disease relevance, and experimental models for GO:1904854.

In simple terms, GO:1904854 means a protein physically binds to the proteasome core complex, the 20S catalytic barrel of the proteasome. The QuickGO definition states binding to a proteasome core complex, and the term is a molecular function. Synonyms include 20S core complex binding, 20S proteasome binding, macropain binding, and PA28gamma-20S proteasome binding. This function is distinct from being a subunit of the core particle; it describes an interaction between a protein and the assembled or assembling core complex.

GO:1904854 matters because the proteasome core complex is the catalytic heart of the ubiquitin-proteasome system, and proteins that bind it control when, where, and how efficiently proteins are degraded. Core-complex binding underlies the ordered assembly of the 20S particle, the docking of regulatory particles and deubiquitinases, and the activation of the 26S holoenzyme. Because proteolysis governs cell-cycle progression, apoptosis, antigen presentation, and protein quality control, perturbations in core-complex binding can shift the balance between protein synthesis and degradation, with consequences for cancer, neurodegeneration, and infection.

The following genes and proteins represent major factors whose products bind or functionally associate with the proteasome core complex and are relevant to GO:1904854.

Proteasome core complex binding is regulated at multiple levels. Assembly chaperones such as Pba3 and Pba4 bind transiently during core particle formation and are released upon maturation, ensuring that only correctly assembled particles proceed. Proteasome-associated deubiquitinases, including USP14, bind the proteasome and regulate its allosteric states, as shown by time-resolved cryo-EM, thereby tuning degradation in response to cellular signals. Ubiquitin-like modifiers provide another layer: FAT10 and NUB1L cooperate to activate the 26S proteasome, linking modifier availability to proteolytic output. In addition, K48-ubiquitin-dependent proteases act on post-ER proteins, connecting core-complex-associated degradation to ER quality control. These regulatory inputs collectively determine when core-complex binding translates into efficient proteolysis.

Cancer cells often depend on high proteasome activity to manage proteotoxic stress, and proteasome assembly and core-complex binding are therefore relevant to tumor biology. Because core particle assembly requires chaperone binding events such as those involving Pba3 and Pba4, perturbations in these steps can alter the pool of active 20S particles. Proteasome-associated deubiquitinases like USP14 further modulate degradation and have been studied structurally, highlighting opportunities for therapeutic intervention. Thus, genes encoding core-complex-binding proteins are candidate biomarkers and targets in cancers with proteasome addiction.

Neurons are particularly sensitive to proteostasis failure, and impaired proteasome function is linked to neurodegenerative disease. Proper core particle assembly, which depends on chaperone binding to alpha-ring intermediates, is required for maintaining a functional 20S core. When core-complex binding or assembly is disrupted, the accumulation of damaged proteins can contribute to neuronal dysfunction. This makes GO:1904854 relevant to understanding how proteasome assembly defects may contribute to neurodegeneration.

TRIM7, an E3 ubiquitin ligase, inhibits enterovirus replication and promotes emergence of a viral variant with increased pathogenicity, linking ubiquitin-dependent proteolysis to antiviral defense. K48-ubiquitin-dependent proteases also cut up post-ER proteins, showing how degradation pathways handle viral and cellular substrates at the ER. Because core-complex binding controls the catalytic core of the proteasome, it indirectly shapes the efficiency of these antiviral degradation events. This connection positions GO:1904854 within host-pathogen interactions.

Native gel electrophoresis, pull-downs, and reconstitution assays can detect binding of proteins to the 20S core particle and resolve assembly intermediates such as the alpha5-alpha6-alpha7-Pba3-Pba4 complex. These methods directly test GO:1904854 by measuring physical association with the core complex. They are typically combined with knockout or point-mutation models to establish causality.

Time-resolved cryo-EM has been used to visualize USP14-regulated allostery of the human proteasome, revealing how binding events change conformational states. Structural approaches define the interfaces that underlie core-complex binding and can guide point-mutation design. They are essential for mechanistic interpretation of GO:1904854.

Mass spectrometry-based proteomics and ubiquitin-chain reporters measure how core-complex binding affects degradation of ubiquitinated substrates. K48-ubiquitin-dependent proteases that cut up post-ER proteins can be monitored to link core-complex function to ER quality control. These readouts connect molecular binding to cellular proteostasis.

Viral infection assays in knockout and overexpression models can test whether core-complex-associated factors such as TRIM7 restrict enterovirus replication. Such functional assays complement biochemical binding data and place GO:1904854 in a physiological context. They are particularly useful for host-pathogen studies.

Researchers studying proteasome core complex binding-related genes often need to determine whether a candidate gene is causally involved in core particle assembly, regulation, or degradation, and CRISPR-based models provide the most direct route to that answer. By combining knockout, point-mutation, knock-in, and overexpression strategies with proteomics and structural readouts, it becomes possible to move from correlation to mechanism for GO:1904854.

GO:1904854, proteasome core complex binding, defines a molecular function at the heart of proteostasis: the selective association of proteins with the 20S catalytic barrel of the proteasome. From chaperone-assisted assembly involving the alpha5-alpha6-alpha7-Pba3-Pba4 unit to deubiquitinase docking by USP14 and activation by FAT10-NUB1L, these binding events control the proteasome's ability to degrade ubiquitinated substrates. The evolutionary conservation of core-complex binding, including in archaea, underscores its fundamental importance. Because core-complex binding is linked to cancer, neurodegeneration, and antiviral defense, it is a compelling area for functional genomics. CRISPR knockout, point-mutation, knock-in, and overexpression models, combined with proteomics and structural biology, provide the tools needed to dissect these mechanisms and to translate them into therapeutic insight.